Hamzeh Kayhanian, Elizabeth C Smyth, Chiara Braconi, Department of Gastrointestinal Oncology, Royal Marsden Hospital, London and Surrey SM2 5PT, United Kingdom
Chiara Braconi, Institute of Cancer Research, London and Surrey SM2 5PT, United Kingdom
Author contributions: Smyth EC and Braconi C should be as the co-corresponding authors; all authors wrote and edited the paper.
Conflict-of-interest statement: Smyth EC declares payment for advisory board participation from Five Prime Therapeutics and for an advisory role from Bristol Meyer-Squibb.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Elizabeth C Smyth, Department of Gastrointestinal Oncology, Royal Marsden Hospital, London and Surrey SM2 5PT, United Kingdom. firstname.lastname@example.org
Telephone: +44-20-86426011 Fax: +44-20-86439414
Received: September 28, 2016
Peer-review started: October 7, 2016
First decision: December 1, 2016
Revised: January 5, 2017
Accepted: March 23, 2017
Article in press: March 24, 2017
Published online: July 15, 2017